Diclofenac Sodium is an NSAID (acetic acid derivative) indicated for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and topically for joint pain. We supply it to US manufacturers of delayed-release tablets, extended-release tablets and topical gel.
Data from PubChem (CID 5018304) and FDA’s substance registry
CAS number
15307-79-6
Molecular formula
C14H10Cl2NNaO2
Molecular weight
318.1g/mol
FDA UNII
IUPAC name
sodium 2-[2-(2,6-dichloroanilino)phenyl]acetate
InChIKey
KPHWPUGNDIVLNH-UHFFFAOYSA-M
- Appearance
- White or slightly yellowish crystalline powder.
- Solubility
- Sparingly soluble in water at 25 °C.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Used in oral, topical and ophthalmic products, each with its own requirements. Diclofenac potassium and diclofenac epolamine are separate APIs.
On the US market
- Reference product
- VoltarenNDA 019201
- Approved ANDAs
- 40 with a marketed product
- Approved forms and strengths
- Delayed-release tablet 25 mg, 50 mg, 75 mg
- Topical solution 1.5%, 2%
- Topical gel 1%, 3%
- Ophthalmic solution 0.1%
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com